JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
JVI Accepts, published online ahead of print on 30 July 2008
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
JVI.01083-08v1
82/20/10017    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Badr, G.
Right arrow Articles by Shoukry, N. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Badr, G.
Right arrow Articles by Shoukry, N. H.

 Previous Article  |  Next Article 

J. Virol. doi:10.1128/JVI.01083-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Early Interferon Therapy for HCV Rescues Poly-functional long-lived CD8+ Memory T Cells

Gamal Badr, Nathalie Bédard, Mohamed S. Abdel-Hakeem, Lydie Trautmann, Bernard Willems, Jean-Pierre Villeneuve, Elias K. Haddad, Rafick P. Sékaly, Julie Bruneau, and Naglaa H. Shoukry*

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montréal, QC, Canada; Faculty of Science, Assiut University, Egypt; Département de microbiologie et immunologie, Département de médecine, Département de médecine familiale, Université de Montréal, Montréal, QC, Canada; Unité INSERM (U-743), Montréal, QC, Canada

* To whom correspondence should be addressed. Email: naglaa.shoukry{at}umontreal.ca.


   Abstract

The majority of acute hepatitis C virus (HCV) infections progress to chronicity and progressive liver damage. Interferon-alpha (IFN-{alpha}) antiviral therapy achieves the highest rate of success when administered early during the acute phase but the underlying mechanisms are unknown. We used a panel of MHC class I tetramers to monitor the phenotypic and functional signatures of HCV-specific T cells during acute HCV with different infection outcome and during early interferon therapy. We demonstrate that spontaneous resolution correlates with the early development of poly-functional (IFN-{gamma}+, IL-2+ and CD107a+) virus-specific CD8+ T cells. These poly-functional T cells are distinguished by the expression of CD127 and Bcl-2 and represent a transitional memory T cell subset that exhibits the phenotypic and functional signatures of both central and effector memory T cells. In contrast, HCV-specific CD8+ T cells in acute infections evolving to chronicity were CD127lo, Bcl-2lo, exhibited diminished proliferation and cytokine production and eventually disappeared from the periphery. Early therapeutic intervention with pegylated IFN-{alpha} (PEG-IFN{alpha}) rescued CD127hi, Bcl-2hi poly-functional memory T cells. These cells were detectable for up to 1 year following discontinuation of therapy. Our results suggest that poly-functionality of HCV-specific T cells can be predictive of the outcome of acute HCV and that early therapeutic intervention can reconstitute the pool of long-lived poly-functional memory T cells.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.